Investigational drug · Phase 2
ABBV-8736
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Crohn's Disease.
Phase 2Last checked: Nov 19, 2026Latest source record: Sep 25, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
3
Any phase or sponsor naming "ABBV-8736"
First trial start
2024
Sep 4, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "ABBV-8736", any sponsor or status.
Conditions studied
As listed on its trial records.
- Crohn's Disease
Approved drugs for the same conditions: Crohn's disease · Immunology and inflammation
Largest trials
Live from ClinicalTrials.gov: studies naming "ABBV-8736" as an intervention, largest first.
- Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's DiseasePivotal-lookingRecruiting
AbbVieAbbVie (ABBV)
NCT06548542 · 590 participants (planned) · Start Sep 4, 2024 · Primary completion Jan 2030
Drug: Risankizumab; Lutikizumab and 4 more · For: Crohn's Disease
Sites: Dothan, Alabama; Mobile, Alabama; Coronado, California · 255 sites in all
AbbVieAbbVie (ABBV)
NCT07413133 · 40 participants · Start Feb 11, 2026 · Primary completion Jun 19, 2026
Drug: ABBV-8736; ABBV-8736 · For: Healthy Volunteer
Sites: Anaheim, California; Grayslake, Illinois
AbbVieAbbVie (ABBV)
NCT07141199 · 24 participants · Start Sep 2, 2025 · Primary completion Mar 23, 2026
Drug: ABBV-8736; Placebo · For: Healthy Volunteer
Sites: Grayslake, Illinois
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Crohn's Disease
- ZasocitinibTAK- 279, NDI-034858Phase 317 trials
Takeda · Plaque Psoriasis, Psoriatic Arthritis, Crohn's Disease
- MK-7240PRA023, TulisokibartPhase 310 trials
Merck & Co. · Ulcerative Colitis, Psoriatic Arthritis, Crohn's Disease
- LutikizumabABT-981Phase 38 trials
AbbVie · Hidradenitis Suppurativa, Atopic Dermatitis, Rheumatoid Arthritis
- DuvakitugSAR447189, TEV-48574 APhase 36 trials
Sanofi · Ulcerative Colitis, Crohn's Disease, Hidradenitis
- JNJ-78934804JNJ-4804Phase 34 trials
Johnson & Johnson (Janssen) · Colitis, Ulcerative, Crohn's Disease, Crohn Disease
- brivekimigSAR442970Phase 25 trials
Sanofi · Focal Segmental Glomerulosclerosis, Glomerulonephritis Minimal Lesion, Type 1 Diabetes Mellitus
- MORF-057zotemtegrast, LY4268989Phase 24 trials
Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company) · Inflammatory Bowel Diseases, Crohn's Disease, Ulcerative Colitis (UC)
- ABBV-701Phase 22 trials
AbbVie · Crohn's Disease, Ulcerative Colitis, Psoriatic Arthritis
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from AbbVie.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.